The non-peptidomimetic cIAP1/2 and XIAP antagonist ASTX660 promotes an anti-tumour immune response in T-cell lymphoma. (October 2020) - Ferrari, N.; Ward, G.; Gewinner, C.; Jueliger, S.; Smyth, T.; Munck, J.; Davis, M.; Ferraldeschi, R.; Lyons, J.; Sims, M.